{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2323852"],"location":["France"],"study_start_month":["1"],"keyword":["Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer","description":"The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer","dates":{"creation":"2020-01-15"},"accession":"2323852","cross_references":{"ClinicalTrials___gov":["NCT04188145"]}}